Controlled-Release MAOI Formulations for Safer Depression Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression and other psychiatric disorders, particularly those involving monoamine oxidase inhibitors (MAOIs), suffer from significant side effects and dietary restrictions, leading to low efficacy and safety concerns, especially for Treatment Resistant Depression (TRD) patients.
Innovation Solution
Development of controlled-release formulations of MAOIs, such as tranylcypromine, phenelzine, and combination therapies with norepinephrine-reuptake-inhibitors (NRIs) to reduce side effects and improve safety by modulating drug release over 6-16 hours, minimizing peak concentrations and interactions with tyramine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MAOIs are used to treat depression, then treatment efficacy is improved, but cardiovascular side effects and dietary restrictions increase
Solution Approach 1:
The patent divides the MAOI drug delivery into multiple segments through controlled-release formulations, including enteric-coated tablets and capsule systems with multiple pellets. This segmentation allows the drug to be released gradually over time rather than all at once, reducing peak plasma concentrations that cause cardiovascular side effects while maintaining therapeutic efficacy throughout the day.
Solution Approach 2:
The patent applies preliminary action by using enteric coating on MAOI tablets before administration. This coating prevents the drug from being released and absorbed in the upper gastrointestinal tract where it would cause immediate peak concentrations. Instead, the coating ensures the drug is protected until it reaches the lower intestine, where it is gradually released, thereby preventing cardiovascular side effects while maintaining treatment efficacy.
2Reliability
If MAOIs are administered to achieve therapeutic effect, then depression treatment is improved, but dietary restrictions and safety concerns increase
Solution Approach 1:
The controlled-release formulations segment the drug release process to maintain steady plasma concentrations of MAOIs throughout the day. This steady-state delivery reduces the formation of toxic metabolites and minimizes tyramine interactions, thereby reducing or eliminating the need for strict dietary restrictions while maintaining therapeutic efficacy for depression treatment.
Solution Approach 2:
The patent introduces an intermediary mechanism through the controlled-release formulation system that acts as a buffer between the MAOI drug and the patient's metabolism. This intermediary release system prevents sudden spikes in drug concentration that would otherwise require strict dietary control, allowing patients to have greater dietary freedom while maintaining treatment efficacy.
3Duration of action of moving object
If conventional MAOI formulations are used, then treatment coverage is achieved, but peak concentrations cause harmful interactions
Solution Approach 1:
The patent implements periodic action through controlled-release formulations that deliver MAOIs at regulated intervals throughout the day. Instead of a single large dose causing harmful peak concentrations, the drug is released periodically at lower concentrations over an extended period, maintaining therapeutic coverage while avoiding toxic peaks and harmful interactions with tyramine-containing foods.
Data Source
AI summary
The invention provides compositions and methods for the treatment of depression and other psychiatric disorders. In particular, the invention provides sustained- or controlled-release formulations, particularly extended or slow release formulations, which include at least one monoamine oxidase inhibitor (MAOI), as well as combination therapies that include at least one MAOI and at least one norepinephrine-reuptake-inhibitor (NRI), for use in such compositions and methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.